Macquarie Group Ltd. lowered its position in shares of SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) by 31.9% during the second quarter, Holdings Channel reports. The firm owned 55,400 shares of the specialty pharmaceutical company’s stock after selling 25,900 shares during the period. Macquarie Group Ltd. owned approximately 0.11% of SciClone Pharmaceuticals worth $724,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Acrospire Investment Management LLC purchased a new stake in SciClone Pharmaceuticals during the first quarter worth $103,000. Mason Street Advisors LLC purchased a new stake in SciClone Pharmaceuticals during the second quarter worth $127,000. Rational Advisors LLC purchased a new stake in SciClone Pharmaceuticals during the second quarter worth $140,000. Profund Advisors LLC purchased a new stake in SciClone Pharmaceuticals during the second quarter worth $141,000. Finally, Suntrust Banks Inc. increased its stake in SciClone Pharmaceuticals by 3.8% in the second quarter. Suntrust Banks Inc. now owns 11,938 shares of the specialty pharmaceutical company’s stock worth $155,000 after buying an additional 432 shares during the last quarter. Hedge funds and other institutional investors own 79.65% of the company’s stock.
Shares of SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) opened at 10.60 on Monday. The company has a market cap of $529.35 million, a P/E ratio of 14.30 and a beta of 1.58. The company has a 50-day moving average price of $10.37 and a 200-day moving average price of $11.77. SciClone Pharmaceuticals Inc. has a 52-week low of $6.47 and a 52-week high of $15.03.
SciClone Pharmaceuticals (NASDAQ:SCLN) last issued its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $0.20 EPS for the quarter. The business earned $39 million during the quarter, compared to analysts’ expectations of $37.90 million. SciClone Pharmaceuticals had a return on equity of 24.43% and a net margin of 24.02%. On average, equities analysts predict that SciClone Pharmaceuticals Inc. will post $0.33 EPS for the current year.
In other SciClone Pharmaceuticals news, CFO Wilson Wai-Shun Cheung sold 7,802 shares of the company’s stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $10.62, for a total value of $82,857.24. Following the completion of the sale, the chief financial officer now owns 25,000 shares in the company, valued at $265,500. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Friedhelm Blobel sold 501,875 shares of the company’s stock in a transaction dated Wednesday, August 17th. The stock was sold at an average price of $10.00, for a total value of $5,018,750.00. Following the completion of the sale, the chief executive officer now owns 588,255 shares of the company’s stock, valued at approximately $5,882,550. The disclosure for this sale can be found here. 7.63% of the stock is owned by company insiders.
SciClone Pharmaceuticals Company Profile
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals Inc. (NASDAQ:SCLN).
Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.